

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number
WO 2022/036041 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) *C07K 14/715* (2006.01)
C12N 5/0783 (2010.01) *C07K 19/00* (2006.01)
C12N 5/10 (2006.01) *A61P 35/00* (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/045668

(22) International Filing Date:

12 August 2021 (12.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/066,039 14 August 2020 (14.08.2020) US

(71) Applicant: **KITE PHARMA, INC** [US/US]; 2400 Broadway, Santa Monica, California 90404 (US).

(72) Inventors: **EMTAGE, Peter**; 1309 Martino Road, Lafayette, California 94549 (US). **FENG, Jun**; 10689 New Grove Trail, Unit #69, San Diego, California 92130 (US). **NOWYHED, Heba**; 10833 Wilshire Boulevard, Apt. 521, Los Angeles, California 90024 (US). **PHUNG, Tammy**; 4168 Twilight Ridge, San Diego, California 92130 (US).

(74) Agent: **GRISWOLD, Ian J.** et al.; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: IMPROVING IMMUNE CELL FUNCTION

(57) Abstract: The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of the tumor microenvironment via improvement in cytokine signaling.

WO 2022/036041 A1